Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Torrent Pharmaceuticals's enterprise value is ₹2,084,561 Mil.
Torrent Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹50,120 Mil. Therefore, Torrent Pharmaceuticals's EV-to-EBITDA for today is 41.59.
The historical rank and industry rank for Torrent Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
NSE:TORNTPHARM'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.9 Med: 20.33 Max: 42.81
Current: 41.59
During the past 13 years, the highest EV-to-EBITDA of Torrent Pharmaceuticals was 42.81. The lowest was 11.90. And the median was 20.33.
NSE:TORNTPHARM's EV-to-EBITDA is ranked worse than 85.67% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.55
vs NSE:TORNTPHARM: 41.59
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Torrent Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Torrent Pharmaceuticals's share price for today is ₹4905.50.
Torrent Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹62.600.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Torrent Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Torrent Pharmaceuticals EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Torrent Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Torrent Pharmaceuticals's EV-to-EBITDA falls into.
Torrent Pharmaceuticals's current Enterprise Value is ₹2,084,561 Mil.
Torrent Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹50,120 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Torrent Pharmaceuticals (NSE:TORNTPHARM) has a EV-to-EBITDA of 41.59 as of Sep. 04, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Torrent Pharmaceuticals. This is 105% above median its historical median of 20.33. Over the past decade, Torrent Pharmaceuticals' EV-to-EBITDA has ranged from 11.90 to 42.81. According to the industry distribution chart, Torrent Pharmaceuticals ranks #622 out of 726 companies in the Drug Manufacturers industry, placing it in the top 85.7%.
Is Torrent Pharmaceuticals' EV-to-EBITDA too high?
Torrent Pharmaceuticals' current EV-to-EBITDA of 41.59 is 105% above median its 10-year median of 20.33. Over the past 10 years, this metric has ranged from a low of 11.90 to a high of 42.81. The Drug Manufacturers industry median EV-to-EBITDA is 13.55. Torrent Pharmaceuticals' value of 41.59 is 206.9% above this industry median. Based on the distribution chart, Torrent Pharmaceuticals ranks #622 out of 726 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Torrent Pharmaceuticals has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Torrent Pharmaceuticals' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Torrent Pharmaceuticals ranks #622 out of 726 companies for EV-to-EBITDA. This places Torrent Pharmaceuticals in the lower half of its industry. The industry median EV-to-EBITDA is 13.55. Torrent Pharmaceuticals' value of 41.59 is 206.9% above this benchmark. Historically, Torrent Pharmaceuticals' own EV-to-EBITDA has ranged from 11.90 to 42.81 over the past decade. While the company's 10-year median is 20.33 vs. the industry median of 13.55, Torrent Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.55, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Torrent Pharmaceuticals's current EV-to-EBITDA of 41.59 is 206.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Torrent Pharmaceuticals. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Torrent Pharmaceuticals's current EV-to-EBITDA is 41.59, which is 105% above median its own 10-year median of 20.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Torrent Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Torrent Pharmaceuticals (NSE:TORNTPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹4,611.60, compared to a current price of ₹4,905.50 — trading 6.4% above its estimated fair value. The current EV-to-EBITDA is 41.59, which is 105% above median its 10-year median of 20.33 and 206.9% above the Drug Manufacturers industry median of 13.55. Torrent Pharmaceuticals' overall GF Score™ is 88/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Torrent Pharmaceuticals (NSE:TORNTPHARM), the current EV-to-EBITDA is 41.59 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Torrent Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹4,905.50 is trading 6.4% above its estimated GF Value™ of ₹4,611.60.
GuruFocus considers Torrent Pharmaceuticals to be Fairly Valued.
Key valuation signals for NSE:TORNTPHARM:
EV-to-EBITDA: 41.59 (105% above median its 10-year median of 20.33)
GF Value™: ₹4,611.60 vs. price of ₹4,905.50 (6.4% above fair value)
Industry Position: 206.9% above the Drug Manufacturers median (#622 of 726)
No single metric tells the full story. See the NSE:TORNTPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Torrent Pharmaceuticals Ltd is a drug manufacturing company with a focus on the cardiovascular, central nervous system, Vitamins Minerals Nutrients (VMN), and gastrointestinal therapeutic areas. It operates through the Generic Formulation Business segment. Geographically, the business activities are carried out across Indian and International markets. Maximum revenue for the company is generated from its operations in India.
88GF Score
Get the complete analysis for NSE:TORNTPHARM
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TORNTPHARM has been successfully added to your 
